Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePractice

Approach to inflammatory breast cancer

Andrea Molckovsky, Barbara Fitzgerald, Orit Freedman, Ruth Heisey and Mark Clemons
Canadian Family Physician January 2009; 55 (1) 25-31;
Andrea Molckovsky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Fitzgerald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orit Freedman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Heisey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Clemons
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mark.clemons@uhn.on.ca
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE To review the definition, clinical presentation, and management of inflammatory breast cancer in primary care.

SOURCES OF INFORMATION Relevant research and review articles, as well as personal experience of the authors practising in a specialized locally advanced breast cancer program at a comprehensive cancer centre. Evidence is levels II and III.

MAIN MESSAGE Inflammatory breast cancer is a rare disease that typically presents with a rapidly enlarging erythematous breast, often with no discernable breast mass. Identification of warning signs and recognition of clinical symptoms are crucial to prompt diagnosis and appropriate referral. Management in the primary care setting includes treatment of symptoms, psychosocial support, regular surveillance and follow-up, as well as palliative care.

CONCLUSION Family physicians are usually the entry point to the health care system and are well positioned to assess inflammation of the breast and recognize the warning signs of an underlying inflammatory breast cancer. They are also important members of the team that provides support for breast cancer patients and their families during treatment, follow-up, and end-of-life care.

The average family physician will see 2 new cases of breast cancer each year.1 Inflammatory breast cancer (IBC) is a rare subgroup of breast cancer that presents particular challenges. Although few women presenting with inflammation of the breast have cancer, family physicians must recognize warning signs and differentiate IBC from the more common benign disorders.

One of the main challenges of IBC is prompt recognition of disease symptoms. Inflammatory breast cancer often presents with diffuse erythema of the breast in the absence of a discrete breast lump, which might not be recognized by patients as a “warning sign” for aggressive breast cancer, thus delaying presentation.2 Clinicians might not recognize IBC warning signs if women are younger, pregnant, or breastfeeding.3 Because IBC is a rapidly progressing form of cancer, it is essential that family physicians be familiar with its clinical presentation and make timely referrals. Following diagnosis, family physicians play an important role in symptom control and supportive care.

In this article we will expound upon basic principles surrounding diagnosis and management of IBC in primary care.

Case 1

Callie is a 36-year-old who gave birth to her first child 2 months ago. Five days ago she noticed redness and tenderness in her left breast. She has no relevant personal past medical history; however, her mother and maternal aunt were both diagnosed with breast cancer in their 60s. Callie presents to your office with visible erythema of the left breast in the upper outer quadrant and concomitant tenderness. She is concerned about infection and breast-feeding on that side. Should you be concerned about IBC?

Case 2

Edith is a 76-year-old widow. She presents to your office complaining of a 3-month history of enlargement of the right breast. Physical examination reveals that her right breast is enlarged and red, and the skin is firm, with pitting (Figure 1). She has palpable axillary lymph nodes. You suspect IBC. What are your next steps in diagnosis and management?

Figure 1
  • Download figure
  • Open in new tab
Figure 1

Right breast is enlarged and red, and the skin is firm, with pitting

Sources of information

Data for this review were identified by a search of MEDLINE (January 1950 to April 2008) using search terms inflammatory breast cancer, detection, differential, risk factors, family physician, and survival. References were hand-searched for relevance and limited to English-language articles. Evidence is level II (epidemiologic studies) and III (reviews based on retrospective case series and expert opinions).

Definition

Inflammatory breast cancer is a clinical diagnosis. Patients typically present with a rapidly progressing, tender, firm, enlarged breast (Table 1). This presentation is due to the invasion of skin dermal lymphatics by breast cancer cells. The obstructed lymph channels produce characteristic skin changes—erythema, warmth, edema, and induration—that mimic an inflammatory process, except cancer cells rather than inflammatory infiltrate are seen under the microscope.4 These changes are sometimes, but not always, demonstrated on skin biopsy.

View this table:
  • View inline
  • View popup
Table 1

Clinical features of inflammatory breast cancer

Epidemiology

Inflammatory breast cancer is not common, representing anywhere from 1% to 6% of all breast cancer diagnoses (level II evidence).5 A recent review suggested that the incidence of IBC could be rising; authors found an incidence of 2% from 1988 to 1990 and 2.5% from 1997 to 1999.5

Inflammatory breast cancer is more common among black women and is associated with younger age at diagnosis (mean age 50 to 58 years compared with 50 to 64 years among those diagnosed with noninflammatory breast cancer).6 Studies based on cases in North Africa, where for unknown reasons 50% of breast cancer cases present as IBC, have suggested an association with obesity and younger age at first giving birth.6 However, there are no validated risk factors that might aid in raising suspicion for IBC.6,7

Inflammatory breast cancer is commonly diagnosed in women who have never had breast cancer, but it can also develop in a breast that contains a known tumour or that has been previously treated. These “secondary” cases of IBC behave similarly to “primary” cases of IBC, and therefore a diagnosis of IBC cannot be excluded in a woman with a known history of breast cancer.8

Clinical presentation

Patients with IBC usually present with a complaint of colour change in 1 breast, usually pink that evolves into a darker red and spreads over the entire breast. The patient might describe a sensation of heat in the breast, and the breast itself enlarges rapidly over a period of only a few weeks (Table 1 and Figure 2). Patients usually do not experience fever.9

Figure 2
  • Download figure
  • Open in new tab
Figure 2
  • Download figure
  • Open in new tab
Figure 2 Patients with inflammatory breast cancer

Patients usually present complaining of colour change in one breast, usually pink that evolves into a darker red and spreads over the entire breast. The patient might describe a sensation of heat in the breast, and the breast itself enlarges rapidly.

Physical examination should focus on assessing warmth, swelling, induration, erythema, and peau d’orange. Nipple changes such as crusting and retraction might be seen but are not criteria for diagnosis.9 Underlying tumour masses might be palpable in IBC, but up to 30% of patients will present with no underlying masses. Instead, such a patient will have a diffusely enlarged breast.9 Given the rapid spread of this type of tumour, it is not uncommon to find axillary adenopathy. Rarely, patients might have signs or symptoms of metastatic spread (Table 2).

View this table:
  • View inline
  • View popup
Table 2

Signs and symptoms of metastatic breast cancer

Certain warning signs in a woman with a red breast increase the likelihood of IBC (Table 3). These include a personal history of breast cancer, nonlactational status, and palpable axillary adenopathy. Unless a clear alternative diagnosis is present, these women should be referred immediately to surgical oncologists.

View this table:
  • View inline
  • View popup
Table 3

Red-flag warning signs of inflammatory breast cancer

Differential diagnoses

The differential diagnoses for inflammation of the breast include benign diseases and other malignancies, and can be stratified by lactation status (Table 4).

View this table:
  • View inline
  • View popup
Table 4 Differential diagnoses of breast inflammation

Entities in boldface are common.

Lactation mastitis occurs in up to 10% of lactating women and is associated with localized tenderness, fever, and leukocytosis—features that help to distinguish it from IBC.10 Mastitis develops rapidly over a few days. The erythema is associated with tenderness and occupies a wedge-shaped quadrant of the breast, and the patient feels unwell. Infection is usually caused by Staphylococcus aureus and improvement occurs within 24 to 48 hours of initiating antibiotics.

Duct ectasia is a benign entity of the nonlactating breast that affects perimenopausal and postmenopausal women. It occurs when ducts beneath the nipples become clogged with fatty material, producing a lump. There is frequently itching or burning around the nipple and a thick discharge.11 These changes are well demarcated and involve less than one-third of the breast.12 Duct ectasia is usually a self-limited disease but might lead to subareolar abscesses that require surgical resection.11

Other benign entities that can be confused with IBC include Mondor disease and fat necrosis. Mondor disease, or phlebitis of the thoracoepigastric vein, usually presents as a painful, possibly palpable, cord and is usually preceded by trauma.10 Because there is a possible association with malignancy, a mammogram is suggested for women older than 35 years of age. Treatment includes reassurance and nonsteroidal anti-inflammatory drugs. Fat necrosis can occur spontaneously or as a result of trauma.10 The usual presentation of fat necrosis is a palpable lump, and a biopsy might be required to differentiate it from malignancy. Neither Mondor disease nor fat necrosis will result in enlarged lymph nodes, another clue to diagnosis of IBC.11

Malignant entities that mimic IBC include leukemic infiltration of the breast. These patients are usually systemically unwell, and a peripheral blood smear usually confirms this rare diagnosis.

Generally, benign breast conditions will resolve with appropriate treatment. Most experts recommend waiting 7 days before initiating further investigations, unless the clinical suspicion of IBC is high (classic breast appearance, axillary nodes, no history of lactation or trauma).

Investigations

If clinical suspicion of IBC is high, prompt referral to a surgeon should be made. Otherwise the first investigation ordered is generally a mammogram. The classic changes that can be seen on a mammogram in IBC are skin thickening, trabecular and stromal thickening, and increased breast density.13 Inflammatory breast cancer, as mentioned, might not be associated with a breast mass, and concomitant high breast density can obscure masses as well; therefore, absence of suspicious masses on the mammogram is not helpful in ruling out IBC.

Ultrasound of the breast and axillary lymph nodes can be useful when IBC is suspected. Ultrasound imaging might detect masses that were not obvious on palpation or mammography, or reveal axillary adenopathy, and thereby facilitate biopsy for diagnosis.13

If results of these investigations do not suggest a benign diagnosis (such as fat necrosis), and the patient’s symptoms persist beyond 3 weeks despite appropriate investigations and conservative treatment (such as nonsteroidal anti-inflammatory drugs and antibiotics), prompt referral to a surgeon is necessary.

Management

Patients with IBC need to be treated promptly, ideally in a multidisciplinary breast oncology clinic that specializes in the treatment of IBC. This patient group requires coordination of medical, surgical, and radiation oncology care as well as nursing and other supportive disciplines. These clinics are usually only found within cancer centres affiliated with tertiary hospitals, and might require patients to travel substantial distances.

Management of IBC encompasses combined-modality therapy. Owing to the skin involvement of IBC, the risk of loco-regional and distant recurrence is too high to justify immediate mastectomy. Preoperative chemotherapy is therefore standard care.14 Before initiating chemotherapy, a core biopsy is performed to confirm the diagnosis and determine hormone-receptor and HER-2/neu status of the tumour. A metastatic workup completes staging. This workup includes bone scans, chest x-ray scans, and abdominal ultrasound scans (with more focused tests if there are any additional symptoms).

The purpose of chemotherapy up front (also known as neoadjuvant or preoperative chemotherapy) is to eliminate micrometastatic disease and reduce inflammation in the breast, making tumours amenable to surgery and radiation. Response to chemotherapy also tells oncologists about the aggressiveness of tumours, providing clues to patients’ ultimate prognoses. After chemotherapy, patients undergo mastectomy and axillary lymph node dissection, followed by radiation therapy to the chest wall and regional lymph nodes.15 The final component of treatment includes endocrine therapy and targeted therapy, such as trastuzumab, depending on receptor status. In total, the active treatment of IBC takes about 1 year.

Common side effects of chemotherapy include alopecia, nausea and vomiting, and risk of febrile neutropenia. Patients are advised to promptly visit the nearest emergency department if they experience a fever (higher than 38°C for at least 1 hour, or 1 reading above 38.2°C). Some patients receiving taxane chemotherapy experience bony pain or myalgias. This pain often responds to treatment with acetaminophen, but can be severe enough to require opioid treatment as well.16 Long-term effects include increased risk of cardiac damage (due to anthracycline therapy) and increased risk of leukemia.

Prognosis

When compared with other breast cancer patients presenting at the same stage, women with IBC have worse prognoses. Moreover, up to 25% of women present with metastatic, incurable disease.17 Median overall survival for IBC patients is 2.9 to 4.2 years,18,19 with lower survival rates among black women and those with estrogen receptor–negative tumours.5 These survival rates have not changed significantly over the past 30 years, emphasizing the aggressive nature of the disease.19 Newer biologic agents such as trastuzumab and lapatinib might improve outcomes for patients with IBC.14 Given the baseline poor prognosis of IBC, eligible patients are offered inclusion in clinical trials if possible.

Family physicians’ role in management

Family physicians are gatekeepers: they play a crucial role in identifying IBC and referring patients appropriately. The oncology team treats the cancer and related problems; however, the family doctor manages nononcologic diagnoses that were present before diagnosis of IBC. Some conditions might be affected by treatment; for instance, blood-glucose control in patients with diabetes often worsens during chemotherapy, owing to steroids given adjunctively. The family doctor often needs to provide psychological support to the patient and her family. Once treatment is finished, close clinical surveillance and annual mammography are shared responsibilities of the oncologist and family doctor. The family doctor also monitors for long-term side effects of treatment (Table 5).

View this table:
  • View inline
  • View popup
Table 5 Family physician follow-up of women treated for breast cancer

The goals of follow-up are to provide support and counseling, to detect metastatic disease and ensure appropriate treatment is initiated promptly, and to provide patient education as new information about breast cancer becomes available.

Often the family physician is not only the patient’s doctor but also her whole family’s doctor. If the patient is the primary caregiver in the family, a shifting of roles needs to occur, and coping can be difficult. Previous relationship difficulties are often exacerbated by the stress of a new diagnosis. Children of any age are substantially affected.20 Family physicians should inquire about children’s health and development; some warning signs include somatic complaints, difficulties with school, depression, and anxiety. Some families might benefit from multidisciplinary support teams that include family physicians, oncologists, nurses, and social workers. Internet resources can also be helpful (Table 6).

View this table:
  • View inline
  • View popup
Table 6

Internet resources

Given the poor prognosis of IBC, family doctors might need to help with palliative care as well. Communication with a patient’s oncologist is essential for optimizing symptom management and organizing end-of-life care. Palliative care clinics affiliated with cancer centres are excellent referral centres that organize home nursing and social work, and they will liaise with family doctors to provide comprehensive and consistent care.

Conclusion

Family physicians are uniquely positioned to assure timely diagnosis of IBC, which is an aggressive form of breast cancer. Prompt recognition of symptoms and signs suggestive of IBC, referral to a multidisciplinary team for treatment, and support of women and their families throughout treatment and beyond assures optimal management of this potentially fatal disease.

Case 1 resolution

Callie has a low-grade fever, and her baby is not feeding properly from the affected breast. Examination reveals a focal area of pain, redness, and induration in the outer upper quadrant, with no palpable lymphadenopathy. Bloodwork results show leukocytosis and left shift. You instruct Callie about compresses, ibuprofen, and continued breastfeeding, and prescribe a 14-day course of oral cloxacillin.11 You expect improvement within 48 hours; if there is no response within 7 days you will reconsider the diagnosis, perform a mammogram and an ultrasound, and, depending on the results, refer Callie to a breast cancer centre.

Case 2 resolution

Edith has many worrisome features of IBC, and prompt mammogram and ultrasound are performed. She is immediately referred to a tertiary oncology centre when pathology from the ultrasound-guided lymph node biopsy reveals breast adenocarcinoma. You help manage her pain and symptoms throughout her ordeal, but despite optimal treatment her cancer spreads and she dies peacefully, pain-free, at a hospice.

Levels of evidence

Level I: At least one properly conducted randomized controlled trial, systematic review, or meta-analysis

Level II: Other comparison trials, non-randomized, cohort, case-control, or epidemiologic studies, and preferably more than one study

Level III: Expert opinion or consensus statements

Notes

EDITOR’S KEY POINTS

  • Inflammatory breast cancer (IBC) is a rare type of breast cancer, accounting for between 1% and 6% of all breast cancer diagnoses. Because IBC is aggressive, however, the prognosis is poorer than for women with other types of breast cancer. Up to 25% of women present with metastatic, incurable disease. Median overall survival for IBC patients is 2.9 to 4.2 years.

  • Patients will usually present with inflammation of the breast. Physical examination should focus on assessing warmth, swelling, induration, erythema, and peau d’orange. Nipple changes might be seen but are not criteria for diagnosis. Up to 30% of patients will not have underlying masses. It is not uncommon to find axillary adenopathy, and signs or symptoms of metastatic spread are rare.

  • Warning signs in a woman with a red breast include a personal history of breast cancer, non-lactational status, and palpable axillary adenopathy. Unless a clear alternative diagnosis is present, these women should be referred immediately to surgical oncologists.

POINTS DE REPÈRE DU RÉDACTEUR

  • Le cancer inflammatoire du sein (CIS) est une forme rare de cancer qui représente entre 1 et 6% de tous les diagnostics de cancer du sein. À cause de son caractère agressif, le CIS présente un moins bon pronostic que les autres types de cancer du sein. Jusqu’à 25% des femmes atteintes ont une maladie métastatique incurable au diagnostic. Globalement, la survie médiane des patientes présentant un CIS est de 2,9 à 4,2 ans.

  • Les patientes consultent généralement pour une inflammation du sein. L’examen physique devrait se concentrer sur la présence de chaleur, d’œdème, d’induration, d’érythème et de peau d’orange. Il se peut qu’il y ait des modifications du mamelon, mais il ne s’agit pas d’un critère diagnostique. Jusqu’à 30% des patientes n’auront pas de masse sous-jacente. Les adénopathies axillaires ne sont pas rares, mais les signes et symptômes d’un envahissement métastatique sont peu fréquents.

  • Les signes à vérifier chez une femme qui a une rougeur au sein sont entre autres des antécédents de cancer du sein, le fait de ne pas être en période d’allaitement et des ganglions axillaires palpables. À moins d’un autre diagnostic évident, ces femmes devraient être immédiatement aiguillées vers un chirurgien oncologiste.

Footnotes

  • Cet article a fait l’objet d’une révision par des pairs.

  • Contributors

    Drs Molckovsky, Freedman, Heisey, and Clemons and Ms Fitzgerald contributed to the concept of the article, the literature search, the review of selected articles, and preparing the manuscript for submission

  • Competing interests

    None declared

  • This article has been peer reviewed.

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    WatsonDEKatzAReidRBogdanBRoosNHeppnerPFamily physician workloads and access to care in Winnipeg: 1991 to 2001CMAJ2004171433942
    OpenUrlAbstract/FREE Full Text
  2. ↵
    BishARamirezABurgessCHunterMUnderstanding why women delay in seeking help for breast cancer symptomsJ Psychosom Res20055843216
    OpenUrlCrossRefPubMed
  3. ↵
    MasonGJohnsonOInflammatory breast cancer: patient advocate viewSemin Oncol20083518791
    OpenUrlCrossRefPubMed
  4. ↵
    CariatiMBennett-BrittonTMPinderSEPurushothamADInflammatory breast cancerSurg Oncol200514313343Epub 2005 Sep 9
    OpenUrlCrossRefPubMed
  5. ↵
    HanceKWAndersonWFDevesaSSYoungHALevinePHTrends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer InstituteJ Natl Cancer Inst2005971396675
    OpenUrlAbstract/FREE Full Text
  6. ↵
    LevinePHVenerosoCThe epidemiology of inflammatory breast cancerSemin Oncol2008351116
    OpenUrlCrossRefPubMed
  7. ↵
    FerdousCSIslamTMMezaLAReview of inflammatory breast cancer: a meta-analysis [abstract]J Clin Oncol200826Suppl1131
    OpenUrl
  8. ↵
    ResetkovaEPathologic aspects of inflammatory breast carcinoma: part 1. Histomorphology and differential diagnosisSemin Oncol20083512532
    OpenUrlCrossRefPubMed
  9. ↵
    SingletarySECristofanilliMDefining the clinical diagnosis of inflammatory breast cancerSemin Oncol2008351710
    OpenUrlCrossRefPubMed
  10. ↵
    GivensMLLuszczakMBreast disorders: a review for emergency physiciansJ Emerg Med20022215965
    OpenUrlPubMed
  11. ↵
    MarchantDJInflammation of the breastObstet Gynecol Clin North Am200229189100
    OpenUrlCrossRefPubMed
  12. ↵
    DahlbeckSWDonnellyJFTheriaultRLDifferentiating inflammatory breast cancer from acute mastitisAm Fam Physician199552392934
    OpenUrlPubMed
  13. ↵
    Le-PetrossCHBidautLYangWTEvolving role of imaging modalities in inflammatory breast cancerSemin Oncol20083515163
    OpenUrlCrossRefPubMed
  14. ↵
    ChiaSSwainSMByrdDRMankoffDALocally advanced and inflammatory breast cancerJ Clin Oncol20082657869
    OpenUrlFREE Full Text
  15. ↵
    BuchholzTATuckerSLMsaulloLPredictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiationJ Clin Oncol20022011723
    OpenUrlAbstract/FREE Full Text
  16. ↵
    FitzgeraldBNapolskikhJSalvoNFreedmanODranitsarisGAliVThe incidence of taxane-induced myopathy in patients receiving chemotherapy for early stage breast cancerPoster presented at: Canadian Association of Medical Oncologists Annual Scientific MeetingMay 2008Toronto, ON
  17. ↵
    WingoPAJamisonPMYoungJLGargiulloPPopulation-based statistics for women diagnosed with inflammatory breast cancer (United States)Cancer Causes Control20041533213
    OpenUrlCrossRefPubMed
  18. ↵
    LowJABermanAWSteinbergSMDanforthDNLippmanMESwainSMLong-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapyJ Clin Oncol20042220406774
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Gonzalez-AnguloAMHennessyBTBroglioKMeric-BernstamFCristofanilliMGiordanoSHTrends for inflammatory breast cancer: is survival improving?Oncologist200712890412
    OpenUrlAbstract/FREE Full Text
  20. ↵
    OsbornTThe psychosocial impact of parental cancer and adolescents: a systematic reviewPsychooncology200716210126
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 55 (1)
Canadian Family Physician
Vol. 55, Issue 1
1 Jan 2009
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Approach to inflammatory breast cancer
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Approach to inflammatory breast cancer
Andrea Molckovsky, Barbara Fitzgerald, Orit Freedman, Ruth Heisey, Mark Clemons
Canadian Family Physician Jan 2009, 55 (1) 25-31;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Approach to inflammatory breast cancer
Andrea Molckovsky, Barbara Fitzgerald, Orit Freedman, Ruth Heisey, Mark Clemons
Canadian Family Physician Jan 2009, 55 (1) 25-31;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case 1
    • Case 2
    • Sources of information
    • Definition
    • Epidemiology
    • Clinical presentation
    • Differential diagnoses
    • Investigations
    • Management
    • Prognosis
    • Family physicians’ role in management
    • Conclusion
    • Case 1 resolution
    • Case 2 resolution
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Idiopathic granulomatous mastitis: a great imitator?
  • Google Scholar

More in this TOC Section

Practice

  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
Show more Practice

Clinical Review

  • Top studies of 2024 relevant to primary care
  • Approach to steatotic liver disease in the office
  • Foreskin care
Show more Clinical Review

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire